More Stories

Informist, Friday, Sept. 19, 2025

 

MUMBAI – Pharmaceutical stocks are likely to be in range with a positive bias, as the market participants are confident that the US administration is likely to strike a deal with India soon, according to analysts. Technical analysts said that the Nifty Pharma index may see an upward movement as it had already reached a breakout point and touched over a two-month high at 22716.90 during Friday's session. 

 

"There is a 99% chance that the pharmaceutical sector may not face any tariffs as it would be a big dent on the pockets of the US citizens, and it will be a tough move for the US administration to impose tariffs on pharmaceutical goods coming in from India ahead of the general elections in November," said Heet Van, Research Analyst at Axis Capital. He said that even if 15-20% tariffs are imposed on the pharmaceutical goods, India is well positioned to cushion the impact as the government is ready to deploy schemes in support of the sector and the rest of the additional costs will be passed on to customers. 

 

Adding to the positive sentiment, rating agency ICRA said Thursday that India's pharmaceutical sector is projected to post healthy revenue growth of 7-9% in 2025-26 (Apr-Mar), aided by robust demand in the domestic and European markets, even as momentum in the US is expected to cool down. 

 

On the negative side, China's decision to slash active pharmaceutical ingredient prices by 40-50% may impact the Indian drug makers, as it is widely seen as Beijing's move to disturb the re-emergence of the Indian active pharmaceutical sector, which was boosted by government incentives, according to analysts. Aurobindo Pharma may see the impact of China's API price cuts, analysts said.

 

The Nifty Pharma index is expected to find support around 22200 levels and encounter resistance around 23100 levels next week, said Brijesh Ail, head of technical and derivatives at IDBI Capital Markets & Securities. For the week ended Friday, Nifty Pharma closed 0.5% higher at 22686.60. IPCA Laboratories was the biggest gainer that ended 10% higher. 

 

TOP HEADLINES

 

* Fire incident temporarily impacts ops of Aurobindo Pharma arm's Andhra unit
* HC warns of penalty on Patanjali Ayurved in chyawanprash case vs Dabur India
* Aurobindo Pharma's denosumab biosimilar not different from Prolia: Study
* Crisil revises Glenmark Pharma long-term bk facilities outlook to 'positive'
* Promoter Jusmiral Holdings offloads 9% stake in Cohance Life via bulk deal
* Biocon arm's Eylea biosimilar drug gets publicly funded in Ontario, Canada
* Sai Life Sciences opens new veterinary API mfg facility in Karnataka
* US FDA tags Natco Pharma's Kothur unit as voluntary action indicated
* Biocon arm gets US FDA nod for biosimilars Bosaya, Aukelso
* Lupin gets approval from US FDA for generic of Revlimid capsules
* US FDA ends inspection at Lupin's Nagpur facility, issues 6 observations
* Authum Investment to buy 3% equity of Serovia Pharma by Sept 20
* Dr Reddy's launches 'Tegoprazan'  in India for gastrointestinal diseases
* India rating ups Alivus Life long-term rtg to AA from AA-, outlook stable
* Zydus Life arm launches two generic drugs in animal health division
* Glenmark Pharma executes pact to transfer consumer care business to arm
* Alembic Pharma gets US FDA establishment inspection report for Panelav unit
* US FDA issues 5 observations to Dr Reddy's biologics mfg unit in Hyderabad
* AstraZeneca gets notice for allegedly overcharging Symbicort Turbuhaler
* In relief to Hikal, Alkem Lab, Blue Jet, HC quashes tax dept notices, orders

 

Following are the resistance and support levels for the stocks for next week as per calculations by Informist based on their prices on the National Stock Exchange:

 

Company	Price	Week-on-Week Change in %	Resistance	Support
Abbott India	30365.00	(-)2.00	31441.70	29591.70
Alkem Laboratories	5541.50	1.70	5627.20	5438.20
Aurobindo Pharma	1119.20	2.30	1145.80	1103.60
Biocon	369.20	1.10	376.50	364.00
Cipla	1575.80	0.10	1600.10	1545.30
Divi's Laboratories	6200.00	2.90	6335.70	6088.70
Dr Reddy's Laboratories	1321.70	0.40	1335.00	1305.40
Gland Pharma	2022.80	0.10	2048.20	1995.20
GlaxoSmithKline Pharmaceuticals	2741.10	(-)1.20	2783.70	2708.70
Glenmark Pharmaceuticals	2085.20	(-)2.20	2134.90	2053.30
Granules India	543.40	1.70	552.80	530.80
Ipca Laboratories	1441.00	9.60	1600.30	1254.10
Laurus Labs	932.10	4.00	958.00	904.20
Lupin	2055.60	0.60	2072.20	2033.20
Natco Pharma	884.25	2.60	897.00	868.70
Pfizer	5107.50	(-)2.30	5225.50	5036.50
Sanofi India	5037.50	(-)0.60	5090.20	5004.20
Sun Pharmaceutical Industries	1656.00	2.40	1680.70	1630.70
Torrent Pharmaceuticals	3629.20	1.80	3681.30	3546.50
Zydus Lifesciences	1037.30	(-)0.70	1068.50	1018.40
Nifty Pharma	22686.60	1.60	22797.60	22525.30
Nifty 50	25327.05	0.90	25489.80	25204.90
S&P BSE Sensex	82626.23	0.90	83189.60	82204.20

 

 

End

 

Reported by P. Madhu Kumar

Edited by Deepshikha Bhardwaj

 

For users of real-time market data terminals, Informist news is available exclusively on the NSE Cogencis WorkStation.

 

Cogencis news is now Informist news. This follows the acquisition of Cogencis Information Services Ltd. by NSE Data & Analytics Ltd., a 100% subsidiary of the National Stock Exchange of India Ltd. As a part of the transaction, the news department of Cogencis has been sold to Informist Media Pvt. Ltd.

 

Informist Media Tel +91 (22) 6985-4000

Send comments to feedback@informistmedia.com

 

© Informist Media Pvt. Ltd. 2025. All rights reserved.